Initial Experience With Ticagrelor in Patients With Critical Limb Ischemia and High On-Clopidogrel Platelet Reactivity Undergoing Complex Peripheral Endovascular Procedures

CardioVascular and Interventional Radiology

Volumn 37, Issue 6, 2014, Pages 1450-1457

  Spiliopoulos, Stavros ^a   Katsanos, Konstantinos ^b   Pastromas, Georgios ^a   Diamantopoulos, Athanasios ^b   Kitrou, Panagiotis ^a   Siablis, Dimitris ^a   Karnabatidis, Dimitris ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clopidogrel; Critical limb ischemia; High on treatment platelet reactivity; Peripheral angioplasty; Stenting; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICAGRELOR; TICLOPIDINE;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; ENDOVASCULAR SURGERY; FEMALE; FOLLOW UP; HUMAN; LEG; LIMB SALVAGE; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY;

ADENOSINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; ENDOVASCULAR PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEG; LIMB SALVAGE; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84893183646     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-014-0852-y     Document Type: Article

References (41)

1. Rooke TW, Hirsch AT, Misra S et al (2013) Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61(14):1555–1570
2. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R (2008) Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil 89(3):422–429
3. Holdsworth RJ, McCollum PT (1997) Results and resource implications of treating end-stage limb ischaemia. Eur J Endovasc Surg 13:164–173
4. Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T (2001) Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: Five-year follow-up. Circulation 104(17):2057–2062
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASCII). Eur J Vasc Endovasc Surg 33(Suppl 1):S1–S75
6. Katsanos K, Spiliopoulos S, Krokidis M, Karnabatidis D, Siablis D (2012) Does below-the-knee placement of drug-eluting stents improve clinical outcomes? Cardiovasc Surg (Torino) 53(2):195–203
7. Siablis D, Karnabatidis D, Katsanos K et al (2009) Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: Analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol 20(9):1141–1150
8. Malyar N, Fürstenberg T, Wellmann J et al (2013) Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. Eur Heart J 34(34):2706–2714
9. Smith SJ, Allen J, Blair S, Bonow R, Brass L, Fonarow G et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372
10. Tepe G, Bantleon R, Brechtel K et al (2012) Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 22(9):1998–2006
11. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D (2013) Platelet responsiveness to clopidogrel treatment after Peripheral endovascular procedures—The PRECLOP study: clinical impact and optimal cut-off value of high on treatment platelet reactivity. J Am Coll Cardiol 61(24):2428–2434
12. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999–3054
13. Cannon CP, Harrington RA, James S, PLATelet inhibition and patient Outcomes investigators et al (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet 375(9711):283–293
14. Montalescot G, Wiviott SD, Braunwald E, TRITON-TIMI 38 investigators et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 28 373(9665):723–731
15. The GUSTO investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682
16. Cannon CP, Husted S, Harrington RA et al (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50:1844–1851
17. Sacks D, Marinelli DL, Martin LG et al (2003) Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol 14(9 Pt 2):S395–S404
18. Matetzky S, Shenkman B, Guetta V et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175
19. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP et al (2005) Platelet reactivity in patients and recurrent events post-stenting results of the prepare post-stenting study. J Am Coll Cardiol 46:1820–1826
20. Bonello L, Tantry US, Marcucci R, for the Working Group on High On-Treatment Platelet Reactivity et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933
21. Spiliopoulos S, Kassimis G, Hatzidakis A, Krokidis M (2013) High on-treatment platelet reactivity in peripheral endovascular procedures. Cardiovasc Intervent Radiol. doi:10.1007/s00270-013-0707-y
22. Pastromas G, Spiliopoulos S, Katsanos K, Diamantopoulos A, Kitrou P, Karnabatidis D et al (2013) Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol 36(6):1493–1499
23. Karnabatidis D, Spiliopoulos S, Pastromas G, Kitrou P, Christeas N, Katsanos K et al (2013) Prevalence of non responsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing. Cardiovasc Intervent Radiol. doi:10.1007/s00270-013-0710-3
24. Ramaraj R, Movahed MR, Hashemzadeh M (2011) Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. J Interv Cardiol 24(3):199–207
25. Abergel E, Nikolsky E (2010) Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag 6:963–977
26. Aradi D, Storey RF, Komócsi A et al (2013) Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 35(4):209–215
27. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB et al (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 124:1132–1137
28. Collet JP, Cuisset T, Rangé G, ARCTIC Investigators et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367(22):2100–2109
29. Spiliopoulos S, Katsanos K, Karnabatidis D et al (2010) Cryoplasty versus conventional balloon angioplasty of the femoropopliteal artery in diabetic patients: long-term results from a prospective randomized single-center controlled trial. Cardiovasc Intervent Radiol 33(5):929–938
30. Dahlen JR, Price MJ, Parise H, Gurbel PA (2013) Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thromb Haemost 109(5):801–808
31. Stone GW, Witzenbichler B, Weisz G, ADAPT-DES Investigators et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 382(9892):614–623
32. Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP (2006) Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. Diabetes Care 29(10):2252–2256
33. Alexopoulos D, Galati A, Xanthopoulou I et al (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. J Am Coll Cardiol 17 60(3):193–199
34. Storey RF, Husted S, Harrington RA et al (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50:1852–1856
35. Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation 120:2577–2585
36. Storey RF, Angiolillo DJ, Patil SB et al (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456–1462
37. Wiviott SD, Braunwald E, McCabe CH, TRITON-TIMI 38 Investigators et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015
38. Wallentin L, Becker RC, Budaj A, PLATO Investigators et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057
39. Gurbel PA, Bliden KP, Butler K et al (2010) Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 121(10):1188–1199
40. Coleman CI, Limone BL (2013) Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients. Cost-effectiveness analyses for six European perspectives. Thromb Haemost 111(1):103–110
41. Nawarskas JJ, Clark SM (2011) Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev 19(2):95–100